BAVA:CPH
Bavarian Nordic A/S
DKK २३६.४०
arrow_downward
-०.१७%(-०.४०) 1D
अक्टोबर १४, १२:२३:२६ GMT+२ · DKK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
DKK २३६.४०
High
DKK २३८.००
Low
DKK २३६.००
Mkt. cap
१९.१२ अरब
Avg. vol.
१.७९ लाख
Volume
१.३६ लाख
52-wk high
DKK २४३.७०
52-wk low
DKK १७१.३०
Shares outstanding
७.९३ करोड
No. of employees
२ हजार
Open
DKK २३६.४०
High
DKK २३८.००
Low
DKK २३६.००
Mkt. cap
१९.१२ अरब
Avg. vol.
१.७९ लाख
Volume
१.३६ लाख
52-wk high
DKK २४३.७०
52-wk low
DKK १७१.३०
Shares outstanding
७.९३ करोड
No. of employees
२ हजार
News stories
From web sources and news partners
GlobeNewswire
·
३४ मिनेट पहिले
Owlting Group (NASDAQ: OWLS) and Decaf Open U.S. Dollar Accounts Beyond the United States on OwlPay Harbor
Reuters
·
२८ मिनेट पहिले
Mapping the Market: Dow eyes another run at a rally
Investor's Business Daily
·
१ घण्टा पहिले
Dow Futures Rise; ASML Earnings Beat, CPI Inflation Due
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S